👋 Hey, let’s get into it. Cher. Madonna. Sting. Novo. Novo Nordisk just joined the one-name club, at least for everyday branding.

The company will now go by “Novo” day to day, though Novo Nordisk A/S remains its legal name. The shorter brand comes with a corporate-culture reset centered on customer obsession, competitiveness, clarity, and care and integrity as the drugmaker tries to make faster decisions and keep pace with Lilly in obesity.

Step one to becoming cool: call yourself a single name. Check. Step two: prove the pipeline and commercial execution can keep up. Still pending.

🧠 Definium’s LSD Drug Goes Three-for-Three in Phase 3
Definium’s LSD-based DT120 ODT has now gone three-for-three in Phase 3 across generalized anxiety disorder and major depressive disorder. In the 245-person PANORAMA trial, a single 100-microgram supervised dose reduced anxiety scores 9.8 points at week 12 versus 4.7 with placebo, a 5.1-point difference. The company plans an FDA meeting in the fourth quarter and a filing in the first half of 2027. The catch is delivery: participants were monitored for at least eight hours. The efficacy case keeps getting stronger. Making an eight-hour dosing session scalable may be the harder problem.

💪 Scholar Rock Wins FDA Approval for First Muscle-Targeted SMA Drug
FDA approved Scholar Rock’s Isembyld, the first treatment designed to directly target muscle in spinal muscular atrophy (SMA), a rare genetic disease that causes motor-neuron loss and progressive muscle weakness. The drug is approved for adults and children ages two and older already receiving an SMN2-targeted treatment. Unlike therapies that increase SMN protein, Isembyld blocks myostatin activation to address remaining muscle weakness. In the main pediatric efficacy group, patients gained 2.2 points more than placebo on a motor-function scale after one year. Fractures occurred in 9% versus 2%. It is an add-on, not a replacement or cure.

🪑 Novartis Shareholder Calls for Board Changes After Drug Setbacks
Artisan Partners’ David Samra wants Novartis to shake up its board after the back-to-back del-desiran and pelacarsen disappointments. The top-20 shareholder called for better acquisition oversight, stronger dealmaking expertise and an acquisition committee, while stopping short of blaming CEO Vas Narasimhan. No board changes have been announced, and one investor does not speak for the entire shareholder base. Still, the pressure turns two clinical setbacks into a governance problem. Novartis’ next acquisition may face much more scrutiny before anyone signs off.

🎯 GSK and Roche’s ADCs Extend Survival in Separate Trials
Two B7-H3 antibody-drug conjugates delivered separate Phase 3 survival wins against topotecan in Chinese patients with relapsed small-cell lung cancer. Hansoh and GSK’s risvutatug rezetecan extended median survival to 18.5 months from 10.3. MediLink and Roche’s tambotatug pelitecan reached 13.3 months versus 9.4. Both reduced the risk of death by 54% within their respective trials, strengthening B7-H3’s case in a difficult disease. But put away the podium: different populations, designs and follow-up mean the two drugs cannot be ranked by comparing those medians.

📊 Ivonescimab Extends Survival Against Keytruda in China
New Phase 3 HARMONi-2 data showed median survival of 30.8 versus 22.6 months in China, strengthening ivonescimab’s case against Keytruda monotherapy.

🔌 Axogen Agrees to Buy BioCircuit for $200M
Axogen agreed to buy BioCircuit for $200 million, adding Nerve Tape, an FDA-approved device that connects severed nerves without conventional sutures.

😕 AstraZeneca and Daiichi’s Enhertu PFS Win Comes With Unfavorable Survival Trend
Enhertu extended progression-free survival by six months in first-line HER2-mutant lung cancer, but immature overall-survival results numerically favored Keytruda plus chemotherapy.

🙌 AbbVie’s Atogepant Wins Menstrual Migraine Trial
Seven-day courses of AbbVie’s atogepant cut 0.8 more menstrual-migraine days than placebo across three cycles, meeting every ranked Phase 3 endpoint.

🏭 GSK Plans Flu-Vaccine Plant Closure
GSK plans to close its Dresden flu-vaccine plant as egg-based shot demand declines, putting 641 jobs at risk, according to its union.

💊 Generic Drug Price Pressure Threatens Supply, AAM Warns
AAM warns concentrated buying and relentless price pressure could push generic manufacturers from unprofitable markets, threatening the durability of low-cost drug supply.

🔄 Cellectis Pivots From Internal CAR-T to In Vivo Editing
Cellectis is shelving internal donor-derived CAR-T programs and redirecting resources toward preclinical in vivo gene editing for cardiovascular disease, while partnered cell-therapy work continues.

✅ FDA Expands Bayer’s Hyrnuo Into Untreated HER2-Mutant Lung Cancer
FDA granted accelerated approval for Bayer’s Hyrnuo in untreated HER2-mutant advanced lung cancer after 75% of 69 patients responded in the single-arm trial.

Most researchers spend their careers designing experiments for the agency. Now the agency wants to run a few experiments on itself. Under the White House’s “golden age of science” agenda, the NSF is rethinking how research gets funded and evaluated.

The NSF announced a new funding strategy built around a portfolio approach, meaning the size and structure of awards could vary with the science being supported. It also named four cross-disciplinary Frontier Initiatives: Future of Intelligence, Frontier of Quantum Phenomena, Advanced Materials and Matter, and Foundations of Biological Design. That last category could touch fields from synthetic biology to tools for understanding and engineering living systems, although specific eligible projects have not been defined.

The agency also plans to create an Office of Metascience, essentially an office for studying how research gets funded, reviewed and managed. It will evaluate new approaches and emerging tools, then scale what works and retire what does not. Even the grant-review process is getting a methods section. The agency also says it will continue supporting the Graduate Research Fellowship Program and other scientific-talent efforts.

The important word is “plans.” The NSF has announced themes, not a fully funded menu of awards. No verified new dollar amount came with the framework, and applicants still lack the solicitations, eligibility rules, deadlines and review criteria needed to act. Nature highlighted unresolved funding questions and concern that new priorities could pressure core research, but the outcome will depend on budgets and implementation.

For biotech readers, biological design and new funding formats could eventually shape academic research, shared infrastructure and startup formation. For now, watch the Dear Colleague Letters and funding notices. A “golden age” makes a nice headline, but researchers still need an opportunity number to work with.

This is the amount of new commitments Frazier Life Sciences added to its Public Fund, bringing the vehicle’s total to $2.8 billion since 2021. It targets small- and mid-cap public biotechs and later-stage crossovers. Commitments are not deployed cash, but specialist investors still have serious money to put to work.

🗣️ Scientists Boycott the ADA
Scientists are pledging to stop reviewing grants and manuscripts or participating in American Diabetes Association activities after five researchers were removed from its June meeting. Signatories want an independent review of the organization’s governance. The ADA says the removals concerned disruptive conduct, not the material being distributed, but later acknowledged its initial findings did not account for the full investigation. Professional societies run on volunteer expertise. Now some of that expertise is walking out.

🤖 Anthropic’s Biology Safeguards Meet Skeptical Scientists
Anthropic says it blocked several biology-related uses of Claude that it classified as potentially dangerous, including assistance connected to research proposals. The disclosure sent biotech Reddit into a familiar debate: can AI safeguards distinguish legitimate science from risky assistance without blocking useful work? Some researchers described frustrating refusals and concerns about entering proprietary research into outside systems. A few frustrated Redditors are not a scientific sample. Still, guardrails become roadblocks when legitimate researchers have no clear way to appeal.

🍄 FDA Hearing Puts Psychedelic-Treatment Logistics on the Table
FDA’s public hearing examined supervision, training, safety monitoring and access for potential psychedelic treatments, without approving a drug or final delivery rules.

🫀 ARPA-H Puts Up to $62.7M Behind Cardiovascular AI
ARPA-H committed up to $62.7 million to build and independently test cardiovascular AI agents, targeting an FDA submission package within 24 months.

🧬 Human-Embryo Study Exposes Limits of Precision Editing
Base editing in early human embryos produced intended PCSK9 changes alongside unwanted deletions, mosaicism and developmental problems under some conditions, highlighting reproductive-safety barriers.

🥬 Lettuce-Linked Cyclospora Outbreak Ends, but FDA Keeps Digging
The outbreak linked to Taylor Farms de Mexico iceberg lettuce is over, but the FDA is still investigating how contamination occurred.

🌱 Caspian Raises $50 Million to Try Restoring Insulin-Producing Cells
Caspian Therapeutics launched with $50 million to test whether menin inhibition can help rebuild the pancreas’s insulin-producing beta-cell capacity. The Kura Oncology spinout is advancing KO-7246, a molecule designed for chronic metabolic use, through IND-enabling studies and toward initial clinical proof of concept. Kura says preclinical work showed beta-cell expansion in animal models and human islet systems. That is an intriguing biological hypothesis, not a diabetes cure. Human safety, durability and, in type 1 diabetes, the underlying autoimmune attack still have plenty to say.

🐢 September 15, 1835: Darwin Arrives in the Galápagos
On this day 191 years ago, Charles Darwin sailed into the Galápagos aboard HMS Beagle and began a five-week visit that would eventually help reshape biology. Darwin did not arrive, glance at a few finches and immediately “invent” evolution. He often failed to record which island his bird specimens came from, and their importance became clearer only after ornithologist John Gould examined them back in England. A famous field trip, years of analysis and one enduring reminder to label your samples.

Novo isn’t the only one entering its one-name era. For celebrity purposes, we’re also going by one name: BioNucleus. So when you, our dear readers, discuss this newsletter with friends and family over dinner, as I’m sure you all do every evening, please refer to us simply as BioNucleus. While we cannot confirm or deny that Cher, Madonna and Sting are avid BioNucleus readers, we’re confident they would expect nothing less.

That’s all for today. See you Thursday for the next issue. 👋

✍️ Today’s email was brought to you by Josh Martin. Connect with me on LinkedIn.

Stop hoping the algorithm finds your audience. They’re already here.

Put your brand in front of 1,600+ scientists, founders, investors, operators, and other biotech and pharma professionals.

Interested in sponsoring an upcoming issue? Reply to this email and let’s talk.

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead